WASHINGTON, July 25, 2024 /PRNewswire/ — Cadmium, the leading learning and event technology provider, has officially concluded the second and final day of Cadmium Spark 2024. The two-day event connected industry leaders through workshops, sessions, and product updates all geared towards sparking innovation for events and education professionals.
The company presented upcoming enhancements and product releases across Cadmium’s suite of event technology tools, specifically how it will empower its users to deliver exceptional event experiences and optimize their event strategies. Advanced registration solutions and seamless session management improvements were also announced, alongside enhanced analytic capabilities.
“These updates are geared towards empowering professionals with the tools they need to stay on top of industry trends,” said Monte Evans, SVP of Products at Cadmium. “I’m proud to lead a team that continually enhances and shapes tools that will revolutionize our client’s events and am excited to see how they will leverage it.”
Other session and workshop highlights included:
Spark 2024 ended with a closing ceremony where awards were presented to:
About Cadmium
Cadmium empowers associations to harness the power of learning experiences by providing an integrated suite of solutions that streamline event management and continuing education. We understand that learning is about transformative moments, and we’re here to help associations share those moments, create community, and drive meaningful change. For more information, visit https://gocadmium.com
Contact:
Jessie Reyes | Cadmium
Director of Marketing
jessie.reyes@gocadmium.com
SOURCE Cadmium
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…